Unlocking the Value of Diagnostic Information to improve Heart Failure Care

Posted on 02.04.2020

Heart Failure (HF) is a prevalent, serious cardiovascular disease, affecting at least 15 million people in Europe. It has detrimental effects on the quality of life and leads to low chances of survival – lower than for most common types of cancer. HF is also one of the leading causes of unplanned hospital readmission, challenging healthcare systems’ sustainability.

Given the complexity of this condition, timely diagnosis, treatment and effective monitoring are vital. Currently, however, missed or late diagnosis and ineffective monitoring often create a significant barrier to optimal and high-quality HF care. MTE has recently developed a case study, which presents the use of diagnostic information as part of the solution to address these shortcomings. The case study explores how the information generated by In-Vitro Diagnostics, such as cardiac biomarkers can bring value to each step of the HF patient journey and to all the stakeholders of the healthcare system. The results of the case study call on policymakers across Europe to better leverage this value and hence improve care plans for HF patients. The case study is based on The Value of Diagnostic Information Concept. Interested to know more? Check out the case here.

European Value-Based Procurement Conference

Join us for the 4th edition of the European Value-Based Procurement Conference which will be held on 15 December 2022.